Relay Therapeutics (RLAY) Accumulated Depreciation (2019 - 2023)

Relay Therapeutics (RLAY) has 5 years of Accumulated Depreciation data on file, last reported at $23.6 million in Q4 2023.

• On a quarterly basis, Accumulated Depreciation rose 28.24% year-over-year to $23.6 million in Q4 2023; TTM through Dec 2023 was $23.6 million, a 28.24% increase from a year earlier, with the FY2023 full-year figure at $23.6 million, up 28.24% from the prior year.
• Accumulated Depreciation for Q4 2023 stood at $23.6 million, up from $18.4 million in the prior quarter.
• Over the last five years, Accumulated Depreciation for RLAY reached as high as $23.6 million in Q4 2023 and fell as low as $7.0 million in Q4 2019.
• Historically, Accumulated Depreciation has averaged $14.8 million across 5 years, with a median of $14.4 million in 2021.
• Across the five-year window, Accumulated Depreciation surged 50.84% in 2020 and rose 27.99% in 2022, its largest moves.
• Year by year, Accumulated Depreciation stood at $7.0 million in 2019, then surged by 50.84% to $10.5 million in 2020, then soared by 36.44% to $14.4 million in 2021, then advanced by 27.99% to $18.4 million in 2022, then grew by 28.24% to $23.6 million in 2023.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $23.6 million in Q4 2023, $18.4 million in Q4 2022, and $14.4 million in Q4 2021.